Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

DHSC publishes guidance for contractors to access extra flu vaccines

The Department of Health and Social Care (DHSC) has published guidance for community pharmacy contractors to access supplies of flu vaccines procured centrally by the government.

After the success of the seasonal flu immunization programme last year, which resulted in a record uptake of flu vaccines, the DHSC aims to “achieve even higher vaccine uptake rates compared to last year,” it said, in guidance published last week.


DHSC has secured an additional supply of influenza vaccines, as a temporary measure for this year only. The vaccines stocks will be available for NHS trusts, general practices and community pharmacies, to replenish local supplies once they run low.

These stocks will be deployed to areas where it is most needed to maximize the uptake.

Moreover, to keep the process easy and quick, DHSC has kept the same supply route through which pharmacies normally receive their flu vaccines.

Contact wholesalers

The additional stocks will arrive in November, and DHSC will sell some of their centrally procured stock to the pharmacy wholesalers, for further sale to pharmacy contractors.

Community pharmacies should contact their wholesaler for details on what stock is available,” the guidance said.

It specified that it has ordered additional stocks of QIVc, QIVe and QIVr to boost supply.

DHSC has also advised contractors to assess the need for more flu vaccine by analysing the uptake rates in eligible cohorts.

To order more contractors should “contact their regular wholesaler to access additional stock and follow the wholesaler’s process for ordering stock”.

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less